Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
07:00am, Wednesday, 13'th May 2026
FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its execut
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
07:00am, Tuesday, 12'th May 2026
This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions FRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
04:41am, Thursday, 07'th May 2026
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
07:36pm, Wednesday, 06'th May 2026
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.2 per share a year ago.
Castle Biosciences Reports First Quarter 2026 Results
04:05pm, Wednesday, 06'th May 2026
Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 36% over Q1 2025 Raising full-year 2026 revenue
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
10:55am, Tuesday, 05'th May 2026
The mean of analysts' price targets for Castle Biosciences (CSTL) points to an 85.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
07:00am, Tuesday, 05'th May 2026
Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus continue to advance awareness and education thro
Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one
Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence r
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
07:00am, Wednesday, 15'th Apr 2026
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will re
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
07:00am, Friday, 10'th Apr 2026
FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has rec
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
04:04pm, Monday, 30'th Mar 2026
Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
02:22am, Monday, 23'rd Mar 2026
Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the company, MarketBeat rep
